Introduction {#section5-1179554918790563}
============

The high heterogeneity of breast cancer explains in part the differences in the morbidity and mortality of this disease. In that sense, molecular and genetic profiling of breast tumors, as well as their classification, has led to a greater diagnostic accuracy, better prediction of patients' clinical evolution, and more appropriate treatment strategies.^[@bibr1-1179554918790563],[@bibr2-1179554918790563]^

Triple-negative breast cancer (TNBC) is a specific subset of tumors characterized by the absence of the 3 most commonly targeted biomarkers considered for breast cancer treatment: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2).^[@bibr3-1179554918790563]^ The TNBC accounts for 15% to 20% of all breast cancer diagnoses and usually has a more aggressive clinical course, with worse evolution within the first 3 to 5 years after diagnosis; early and higher rates of distant recurrences, typically visceral; and poor survival.^[@bibr3-1179554918790563][@bibr4-1179554918790563]--[@bibr5-1179554918790563]^ There are differences in the natural history and prognosis within TNBC. Recent studies, using next-generation sequencing, for instance, have shown that TNBC is actually a group of distinct tumors displaying different clinical and biological features.^[@bibr6-1179554918790563][@bibr7-1179554918790563]--[@bibr8-1179554918790563]^

It has been proposed to classify TNBC into subgroups: basal-like 1 and 2, mesenchymal, and luminal androgen receptor.^[@bibr6-1179554918790563]^ Novel targets, such as the epithelial growth factor receptor, have emerged as a new drug target. BRCA1 mutation studies have raised expectations for the use of DNA-damaging agents and androgen receptors in the management of TNBC. However, the response to therapy varies considerably, making it difficult to establish a treatment that covers all cases, as a single target has not yet been identified.^[@bibr6-1179554918790563][@bibr7-1179554918790563]--[@bibr8-1179554918790563]^

Anthracycline and taxane-based chemotherapy has traditionally been the mainstay of TNBC therapy in clinical practice.^[@bibr9-1179554918790563]^ Therefore, part of the patients, notably those with initial tumors, receives aggressive treatment without significant improvement in overall survival but rather a worsening quality of life. This scenario highlights the need to research drugs capable of overcoming chemoresistances and reduce the damage of cytotoxic therapy.^[@bibr9-1179554918790563],[@bibr10-1179554918790563]^

Identifying TNBC with a high probability of responding to traditional chemotherapy poses a challenge in current clinical practice. The role of cell proliferation markers, especially the nuclear antigen Ki67, has been emphasized as a prognostic marker and predictor of response to chemotherapeutic regimens, although an optimal cutoff point has not yet been defined.^[@bibr11-1179554918790563][@bibr12-1179554918790563]--[@bibr13-1179554918790563]^ Lymphocytic infiltration has also been found to be a prognostic and predictive marker of response to both neoadjuvant and adjuvant therapies.^[@bibr14-1179554918790563][@bibr15-1179554918790563]--[@bibr16-1179554918790563]^

Therefore, studies are needed to enhance the understanding of the TNBC spectrum, to improve current management and patient outcome. It is possible that tumor grade, histological type, lymphocytic infiltration, and cell division markers would have some interface with the complex information of genetic and molecular assays, thus providing estimates of clinically relevant TNBC subgroups.^[@bibr16-1179554918790563][@bibr17-1179554918790563]--[@bibr18-1179554918790563]^ How these parameters occur in TNBC and their relation to survival and disease relapse have been inadequately investigated in Brazil. This study thus aimed to identify clinical and pathological features in a cohort of Brazilian women diagnosed with breast cancer, comparing TNBC with non-TNBC tumors, and to assess possible associations of the parameters with recurrence and survival.

Patients and Methods {#section6-1179554918790563}
====================

Study population {#section7-1179554918790563}
----------------

This hospital-based retrospective cohort study comprised women diagnosed with breast cancer between 2003 and 2005. They were assisted at a public and a private referral center for cancer care in the city of Juiz de Fora, state of Minas Gerais, Brazil. The patients were identified through the Hospital Registry of Cancer, and data were obtained through a standardized form from the medical records of both cancer and breast specialists.

A total of 563 patients were initially identified. Women diagnosed with carcinoma in situ were excluded (n = 45), as well as those with distant metastasis at diagnosis (n = 39). In addition, 32 patients were excluded because of missing information on the immunochemistry profile. The final cohort consisted of 447 patients, who were classified into 2 groups: TNBC, when tumors were negative for ER, PR, and HER2 (n = 87), and non-TNBC, for all other cases (n = 360).

The immunohistochemical analysis was performed in the hospitals' accredited laboratory following standard criteria. It started with tissue deparaffinization, followed by antigen recovery using wet heat and buffers. Blockage of peroxidases was performed, and specific antibodies were added: SP1 and SP2 for estrogen and progesterone and SP3 or 4B5 for HER2 (dilution: 1/250). The bound antibodies were displayed by the streptavidin-biotin system. A tumor was classified as positive for ER and PR when \>10% of tumor cell nuclei expressed these antigens. For HER2, a positive score of 3+ for membrane staining was required, whereas those with scores of + and 2+ were sent to fluorescence in situ hybridization. This approach meets the American Society of Clinical Oncology 2007 and 2013 recommendations. All laboratory reports were revised.

Study variables {#section8-1179554918790563}
---------------

The following sociodemographic variables were analyzed: age at diagnosis (in years); ethnicity (white or nonwhite); education level (high \[secondary school or higher\], moderate \[primary school\], or low \[incomplete primary school or illiterate\]). The nature of the oncology service (public or private) was also analyzed. Variables related to tumor characteristics included anatomopathological tumor size (⩽2.0 and \>2.0 cm), histological type, lymph node involvement, staging according to TNM classification,^[@bibr19-1179554918790563]^ lymphocytic infiltration (presence or absence), Ki67 (low ⩽25% and high/moderate ⩾26%), p53, multifocality, and multicentricity. Treatment variables were surgery type (radical or conservative) and additional therapy (chemotherapy).

Follow-up {#section9-1179554918790563}
---------

A 5-year follow-up of each patient was conducted based on the consultation of medical records and was complemented by search in the Brazilian Mortality Information System (SIM) of Minas Gerais, telephone contact, consultation of the National Health Registry, and Brazilian individual registration number (CPF).

The diagnosis date (corresponding to the date of the histopathological disease report) was considered the starting point for the analysis of overall survival, and all-cause mortality was used as failure in this case. Disease-free survival was defined as the interval between the first treatment and recurrence (locoregional recurrence, metastasis, or death from any cause).^[@bibr20-1179554918790563]^ Patients who remained alive until December 31, 2010 (the end of follow-up), were censored. The date of the last contact was used to define the end point for loss to follow-up.

Data analysis {#section10-1179554918790563}
-------------

Differences in the distribution of study variables between TNBC and non-TNBC were evaluated by χ^2^ test. Survival functions were calculated using the Kaplan-Meier method, and the log-rank test was used to compare the survival curves. Prognostic factors of overall survival and disease-free survival were analyzed by the Cox proportional hazards model, and the hazard ratios (HRs) were calculated with a 95% confidence interval (CI). Variables that presented *P* values of \<.25 in the univariate Cox model were included in the multivariate model. The risk proportionality assumption was validated by the Schoenfeld residue analysis. For variables with missing data (tumor grade, Ki67, and p53), a comparative study was performed, considering tumor profile, recurrence, metastasis, and death as dependent variables. No significant differences were found between patients with missing data and other patients, showing that data losses were random, which made the analysis of those variables possible. A 5% level of significance was used for all tests. The IBM Statistical Package for the Social Sciences (SPSS) 21 (IBM Corp., Armonk, NY, USA) was used for all statistical analyses.

The study design was approved by the Ethics Committee of Universidade Federal de Juiz de Fora (protocol no. 151.219 of November 22, 2012). The need for informed consent was waived owing to the noninterventional design of the survey and full data protection.

Results {#section11-1179554918790563}
=======

The TNBC accounted for 19.5% of the 447 patients. The mean age at diagnosis did not differ between the groups, and significant differences were identified for ethnicity and educational level, with TNBC being more prevalent in nonwhite women and those with moderate and low education level. The TNBC tended to present at diagnosis with lymphocytic infiltration (*P* = .02), multifocality (*P* = .04), tumor size of \>2 cm (*P* = .06), and stage III tumors (*P* = .09), and to express high levels of p53 (*P* = .04) and Ki67 (*P* = .09). The patients with TNBC showed significantly higher percentages of radical surgery and chemotherapy. When outcomes were compared, the TNBC group presented a higher frequency of early recurrences, defined as up to 24 months (*P* = .02), and death in 5 years (*P* \< .001) ([Table 1](#table1-1179554918790563){ref-type="table"}).

###### 

Distribution of variables according to breast cancer subtype (Juiz de Fora, Brazil, 2003-2005).

![](10.1177_1179554918790563-table1)

  Variable                   Breast cancer subtype                            
  -------------------------- ----------------------- ----------- ------------ --------
  No. of patients            447                     87 (19.5)   360 (80.5)   
  Age at diagnosis           447                     57 (±13)    58 (±14)     .49
  Ethnicity                  422                                              .001
   White                     340                     57 (67.9)   283 (83.7)   
   Nonwhite                  82                      27 (32.1)   55 (16.3)    
  Education level            404                                              .007
   High                      166                     22 (27.8)   144 (44.3)   
   Moderate                  68                      21 (26.6)   47 (14.5)    
   Low                       170                     36 (45.6)   134 (41.2)   
  Family history of cancer   416                                              .3
   Positive                  120                     19 (24.1)   101 (30)     
   Negative                  296                     60 (75.9)   236 (70)     
  Health service             447                                              .14
   Public                    220                     49 (56.3)   171 (47.5)   
   Private                   227                     38 (43.7)   189 (52.5)   
  Tumor size, cm             438                                              .06
   \>2                       257                     58 (67.4)   199 (56.5)   
   ⩽2                        181                     28 (32.6)   153 (43.5)   
  Lymph node involvement     437                                              .64
   Positive                  198                     40 (47.6)   158 (44.8)   
   Negative                  239                     44 (52.4)   195 (55.2)   
  Staging                    446                                              .09
   I                         124                     18 (20.9)   106 (29.4)   
   II                        190                     35 (40.7)   155 (43.1)   
   III                       132                     33 (38.4)   99 (27.5)    
  Histological type          446                                              .21
   Invasive ductal           352                     73 (83.9)   279 (77.7)   
   Invasive lobular          56                      6 (6.9)     50 (13.9)    
   Other                     38                      8 (9.2)     30 (8.4)     
  Tumor grade                337                                              \<.001
   I                         111                     10 (14.9)   101 (37.4)   
   II                        158                     33 (49.3)   125 (46.3)   
   III                       68                      24 (35.8)   44 (16.3)    
  Lymphocytic infiltration   427                                              .02
   Positive                  186                     44 (55.7)   142 (40,8)   
   Negative                  241                     35 (44.3)   206 (59.2)   
  Ki67                       349                                              .09
   ⩽25%                      94                      15 (19.5)   79 (29)      
   ⩾26%                      255                     62 (80.5)   193 (71)     
  p53                        336                                              .04
   ⩽25%                      230                     37 (57.8)   193 (71)     
   ⩾26%                      106                     27 (42.2)   79 (29)      
  Multifocality              423                                              .04
   Positive                  35                      11 (14.1)   24 (7)       
   Negative                  388                     67 (85.9)   321 (93)     
  Multicentricity            422                                              .25
   Positive                  21                      6 (7.7)     15 (4.4)     
   Negative                  401                     72 (92.3)   329 (95.6)   
  Surgery                    442                                              .01
   Radical                   217                     53 (61.6)   164 (46.1)   
   Conservative              225                     33 (38.4)   192 (53.9)   
  Chemotherapy               447                                              .001
   Yes                       308                     73 (83.9)   235 (65.3)   
   No                        139                     14 (16.1)   125 (34.7)   
  Recurrence                 447                                              .001
   Yes                       126                     37 (42.5)   89 (24.7)    
   No                        321                     50 (57.5)   271 (75.3)   
  Time to recurrence, mo     126                                              .02
   Up to 24                  61                      25 (67.5)   36 (40.4)    
   25-36                     26                      6 (16.2)    20 (22.5)    
   37-60                     39                      6 (16.2)    33 (37.1)    
  5-y overall survival       447                                              \<.001
   Dead                      102                     33 (37.9)   69 (19.2)    
   Alive                     345                     54 (62.1)   291 (80.8)   

Abbreviation: TNBC, triple-negative breast cancer.

Total varies due to missing data.

The 5-year overall and disease-free survival rates for the entire patient population were 77% and 72%, respectively. Overall survival was 62% for TNBC and 81% for non-TNBC, and disease-free survival was 57% for TNBC and 75% for non-TNBC (log-rank *P* \< .001; [Figure 1](#fig1-1179554918790563){ref-type="fig"}). The median survival time was 46 months (95% CI: 42-51) for TNBC versus 55 months (95% CI: 54-57) for non-TNBC, and the median disease-free interval was 43 months (95% CI: 38-48) and 53 months (95% CI: 41-54), respectively.

![Overall and disease-free survival in patients with triple-negative breast cancer (TNBC) and non-TNBC (Juiz de Fora, Brazil, 2003-2005).](10.1177_1179554918790563-fig1){#fig1-1179554918790563}

Overall survival: TNBC, 62.7% (95% CI: 51.9-71.2); non-TNBC, 81.1% (95% CI: 76.3-84.5); log-rank test *P* \< .001.

Disease-free survival: TNBC, 57.5% (95% CI: 46.4-67.1); non-TNBC, 75.3% (95% CI: 70.5-79.4); log-rank test *P* \< .001.

Univariate Cox regression analysis showed that the risk of recurrences (HR: 2.23; 95% CI: 1.52-3.28) and risk of death (HR: 2.97; 95% CI: 1.96-4.50) were higher in TNBC compared with non-TNBC. In non-TNBC patients, the risk of recurrence was higher among patients aged \<40 years, of nonwhite ethnicity, with lower education level, and with tumors larger than 2 cm, of grade III and at stage III. Lymph node involvement, p53, Ki67, and chemotherapy treatment were also associated with higher recurrence in this group. In patients with TNBC, only lymph node involvement and staging were associated with recurrence ([Table 2](#table2-1179554918790563){ref-type="table"}).

###### 

The 5-year disease-free survival estimated by univariate Cox analysis for 447 women diagnosed with breast cancer (Juiz de Fora, Brazil, 2003-2005).

![](10.1177_1179554918790563-table2)

  Variable                   TNBC   Non-TNBC                               
  -------------------------- ------ ------------ ----- ------ ------------ --------
  Age at diagnosis, y                                                      
   \<40 vs ⩾40               1.15   0.28--4.77   .85   1.91   1.10-3.34    .02
  Ethnicity                                                                
   Nonwhite vs white         1.47   0.76--2.88   .26   1.91   1.16--3.16   .01
  Education level                                                          
   Low/moderate vs high      1.55   0.67--3.58   .3    1.92   1.19--3.10   .01
  Health services                                                          
   Public vs private         1.16   0.60--2.24   .66   1.4    0.92--2.12   .12
  Chemotherapy                                                             
   Yes vs no                 0.9    0.38--2.17   .82   1.74   1.08--2.82   .02
  Tumor size, cm                                                           
   \>2 vs ⩽2                 1.4    0.67--2.90   .37   2.58   1.59--4.19   \<.001
  Lymph node involvement                                                   
   Positive vs negative      2.15   1.07--4.31   .03   2.28   1.47--3.53   \<.001
  Tumor grade                                                              
   III vs I-II               0.88   0.42--1.82   .73   2.23   1.28--3.89   .01
  Staging                                                                  
   III vs I-II               1.89   0.98--3.64   .05   3.89   2.56--5.90   \<.001
  p53                                                                      
   Moderate/high vs low      1.07   0.53--2.16   .86   1.88   1.16--3.05   .01
  Ki67                                                                     
   Moderate/high vs low      0.91   0.39--2.11   .83   2.06   1.08--3.94   .03
  Multifocality                                                            
   Yes vs no                 1.53   0.63--3.68   .34   1.62   0.81--3.22   .17
  Multicentricity                                                          
   Yes vs no                 2.46   0.87--7.01   .09   1.7    0.74--3.90   .21
  Lymphocytic infiltration                                                 
   Positive vs negative      1.47   0.74--2.92   .27   1      0.65--1.54   .99

Abbreviations: CI, confidence interval; HR, hazard ratio; TNBC, triple-negative breast cancer.

Overall survival in TNBC was negatively associated with lymph node involvement, stage III, and metastasis during the course of the disease. For the non-TNBC group, poorer survival was observed in patients of nonwhite ethnicity, with lower education level, who were attended in the public health sector, with tumors larger than 2 cm, of grade III and at stage III, lymph node involvement, elevated Ki67, and metastasis during the course of the disease ([Table 3](#table3-1179554918790563){ref-type="table"}).

###### 

The 5-year overall survival estimated by univariate Cox analysis for 447 women diagnosed with breast cancer (Juiz de Fora, Brazil, 2003-2005).

![](10.1177_1179554918790563-table3)

  Variable                   TNBC   Non-TNBC                                     
  -------------------------- ------ ------------- -------- ------- ------------- --------
  Age at diagnosis, y                                                            
   \<40 vs ⩾40               1.06   0.25--4.43    .94      1.65    0.87--3.15    .13
  Ethnicity                                                                      
   Nonwhite vs white         1.51   0.75--3.04    .25      2.41    1.41--4.12    .001
  Education level                                                                
   Low/moderate vs high      1.66   0.68--4.08    .27      2.05    1.17--3.61    .01
  Health services                                                                
   Public vs private         1.42   0.70--2.89    .33      1.82    1.13--2.46    .01
  Chemotherapy                                                                   
   Yes vs no                 0.75   0.31--1.81    .52      1.34    0.79--2.25    .27
  Tumor size                                                                     
   \>2 vs ⩽2 cm              1.37   0.63--2.95    .43      3.29    1.82--5.94    \<.001
  Lymph node involvement                                                         
   Positive vs negative      2.72   1.27--5.82    .01      2.25    1.36--3.73    .002
  Metastasis                                                                     
   Positive vs negative      13.5   5.36--34.03   \<.001   14.75   8.42--25.83   \<.001
  Tumor grade                                                                    
   III vs I-II               1.01   0.47--2.19    .98      2.87    1.55--5.29    .001
  Staging                                                                        
   III vs I-II               2.18   1.09--4.37    .03      3.93    2.44--6.32    \<.001
  p53                                                                            
   Moderate/high vs low      1.06   0.50--2.23    .88      1.51    0.86--2.63    .15
  Ki67                                                                           
   Moderate/high vs low      0.98   0.40--2.40    .97      2.12    1.00--4.50    .05
  Multifocality                                                                  
   Yes vs no                 1.51   0.62--3.68    .37      0.81    0.29--2.22    .68
  Multicentricity                                                                
   Yes vs no                 2.67   0.93--7.65    .07      1.79    0.72--4.45    .21
  Lymphocytic infiltration                                                       
   Positive vs negative      1.57   0.75--3.28    .23      1.01    0.50--1.35    .82

Abbreviations: CI, confidence interval; HR, hazard ratio; TNBC, triple-negative breast cancer.

The multivariate analysis revealed that lymph node involvement appears to increase the risk of recurrence and mortality in patients with TNBC. Multicentricity was also associated with a higher risk of death in this group. In non-TNBC patients, the risk of recurrence was higher in those with lower education level and lymph node involvement, and survival was worse in nonwhite women and those with advanced-stage tumors ([Table 4](#table4-1179554918790563){ref-type="table"}). For all multivariate models, the proportional hazards assumption was confirmed overall and separately for each variable by the scaled Schoenfeld residual test.

###### 

The 5-year disease-free and overall survival estimated by multivariate Cox analysis for 447 women diagnosed with breast cancer (Juiz de Fora, Brazil, 2003-2005).

![](10.1177_1179554918790563-table4)

                           Disease-free survival   Overall survival                              
  ------------------------ ----------------------- ------------------ ----- ------ ------------- --------
  TNBC                                                                                           
  Lymph node involvement                                                                         
  Positive vs negative     2.28                    1.12--4.57         .02   2.8    1.26--6.25    .012
  Multicentricity                                                                                
  Yes vs no                ---                     ---                ---   4.11   1.17--14.36   .027
  Non-TNBC                                                                                       
  Ethnicity                                                                                      
  White vs nonwhite        ---                     ---                ---   2.01   1.17--3.45    .01
  Education level                                                                                
  Low/moderate vs high     1.91                    1.14--3.22         .01   ---    ---           ---
  Lymph node involvement                                                                         
  Positive vs negative     1.81                    1.14--2.90         .01   ---    ---           ---
  Staging II                                                                                     
  II vs I                  ---                     ---                ---   3.06   1.16--8.05    .02
  Staging III                                                                                    
  III vs I                 ---                     ---                ---   8.36   3.27--21.36   \<.001

Abbreviations: CI, confidence interval; HR, hazard ratio; TNBC, triple-negative breast cancer.

All models were adjusted for age at diagnosis, in continuous format.

Discussion {#section12-1179554918790563}
==========

This study described the clinical, pathological, and sociodemographic characteristics of patients with TNBC and non-TNBC in a medium-size city in Southeastern Brazil, which is a regional reference for cancer care. The TNBC prevalence in this study is in accordance with the literature, as it accounts for 10% to 20% of all breast cancers.^[@bibr2-1179554918790563],[@bibr5-1179554918790563],[@bibr21-1179554918790563]^ The TNBC was more likely to be found in nonwhite women than non-TNBC, which is expected because TNBC is more common in women of African ancestry or Hispanic ethnicity.^[@bibr22-1179554918790563],[@bibr23-1179554918790563]^ Despite lower incidences of breast cancer in black and Hispanic women, studies have persistently shown that these women are more commonly affected by tumors with increased severity and worse outcomes.^[@bibr22-1179554918790563][@bibr23-1179554918790563][@bibr24-1179554918790563]--[@bibr25-1179554918790563]^

Although TNBC is frequently diagnosed in younger patients,^[@bibr2-1179554918790563],[@bibr5-1179554918790563],[@bibr21-1179554918790563]^ the mean age at diagnosis in our study cohort was 57 years, which may partly reflect late diagnosis or difficult access to health care services. The higher percentage of TNBC in women with lower education level and assisted in the public health sector is consistent with the higher occurrence of TNBC in socially disadvantaged populations.^[@bibr22-1179554918790563],[@bibr26-1179554918790563]^ Other demographic variables such as parity, breastfeeding, reproductive status, and family history did not seem to differ in the 2 groups.

Similar to findings in other studies, the 5-year overall and disease-free survival were worse in women with TNBC.^[@bibr2-1179554918790563],[@bibr4-1179554918790563],[@bibr5-1179554918790563],[@bibr21-1179554918790563],[@bibr22-1179554918790563],[@bibr27-1179554918790563]^ About 38% of patients with TNBC died during the 5-year follow-up, compared with only 19% of non-TNBC patients. Recurrences were observed in 43% of patients with TNBC, compared with 25% in non-TNBC patients. Not only were recurrences more prevalent in the TNBC group but they also occurred earlier in the course of the disease. In the patients with TNBC, 67.5% of recurrences were found within the first 2 years and 83.7% within the first 3 years after diagnosis, whereas in the non-TNBC group, these values were 40.4% and 62.9%, respectively. These recurrence rates were higher than those observed in a Chinese cohort (2016), in which the 5-year recurrence was 27.5% in the patients with TNBC and 13.4% in non-TNBC patients; the 5-year overall survival rates were 88.5% and 95.5%,^[@bibr28-1179554918790563]^ respectively, higher than those found in our study (62.1% in TNBC and 80.8% in non-TNBC). These differences are probably due the fact that 28% of TNBC and 14% of non-TNBC were diagnosed at stage III (advanced stage) in the Chinese cohort, whereas in our study, these rates were 38% and 28%, respectively. In a Taiwan cohort study, worse survival was also observed in the patients with TNBC, but disease-free survival had no difference when compared with non-TNBC patients.^[@bibr29-1179554918790563]^

Survival rates in this study were also similar to those found in another Brazilian cohort, in which TNBC women without lymph node involvement had a survival rate of 69% in 5 years and 61.6% in 10 years. Among non-TNBC patients, the survival was 82.2% and 70.1% in 5 and 10 years, respectively. In that study, skin involvement, histological grade, and Ki67 were identified as prognostic and predictive factors.^[@bibr27-1179554918790563]^ In another Brazilian study, the 5-year survival was 67.8% in TNBC, which was lower compared with non-TNBC subtypes (86.4% for luminal A tumors and 91.4% for luminal B tumors).^[@bibr30-1179554918790563]^

Here, lymph node involvement was a prognostic factor for both mortality and recurrence in the TNBC group, representing a nearly 3 times risk of mortality. The same was observed in an American cohort, in which a 5-year overall survival of 80% was reported for the patients with TNBC without lymph node involvement, compared with 65% in those with up to 3 positive lymph nodes.^[@bibr31-1179554918790563]^ The 5-year survival in this study decreased from 77.3% to 50% (*P* = .004) in the patients with TNBC in the case of positive lymph node involvement.

Our study confirms recent findings on the prognostic role of multicentricity in TNBC, which has been related to higher cell proliferation indexes and tendency to early axillary involvement.^[@bibr32-1179554918790563],[@bibr33-1179554918790563]^ A recent meta-analysis including 67 557 patients with breast carcinoma identified multifocality or multicentricity in 9.5% of them. On multivariate analysis, multicentricity was associated with worse overall survival (HR: 1.65; *P* = .02),^[@bibr34-1179554918790563]^ which is similar to the findings of our study. It seems, therefore, that due to its relevance and independent prognostic value, multicentricity should be considered in the individual management and treatment of patients with TNBC.^[@bibr35-1179554918790563]^

In the non-TNBC group, lymph node involvement was associated with more frequent recurrence and advanced-stage tumors were related to worse survival. The mortality in patients with non-TNBC diagnosed at stage III was 8 times higher compared with that at stage I. In addition to biological variables, sociodemographic variables such as ethnicity and education level were associated with poorer outcomes in non-TNBC, which has also been identified in several studies.^[@bibr22-1179554918790563][@bibr23-1179554918790563]--[@bibr24-1179554918790563],[@bibr26-1179554918790563]^ Those variables possibly did not remain statistically significant on multivariate analysis in TNBC due to the smaller sample size of this group. However, it remains unclear as to what extent the prognosis of TNBC can be attributable to sociodemographic and biologic variables,^[@bibr36-1179554918790563]^ although this study's findings support the second one.

The small sample size, its retrospective design, and performing this study in only one city were major limitations. However, the standardized method of data collection, the use of stratified multivariate models, and the analysis of data from both private and public sectors probably resulted in less likely bias. The statistical analysis showed that data losses were random, partially overcoming the missing data limitation. Finally, the miscegenation of the Brazilian population needs to be considered when comparing the results with other populations. It is noteworthy that despite this factor, patients with TNBC and non-TNBC patients still presented markedly different characteristics, which were generally similar to other population groups. The heterogeneity of TNBC is inter- and intratumoral, and different population studies have yet to provide a common factor that could be used in the therapy of this disease.

Conclusions {#section13-1179554918790563}
===========

The TNBC exhibited distinct sociodemographic and tumor characteristics, as it was more prevalent in nonwhite and less educated women and was diagnosed at a later stage of the disease. This tumor subtype tended to display a worse clinical course, with earlier and more frequent recurrence and worse 5-year survival, compared with non-TNBC. A more aggressive behavior was notably seen in patients with TNBC with lymph node involvement and multicentricity, important clinical features to be considered in the management of these patients.
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